Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Registrational study of SD 101

Trial Profile

Registrational study of SD 101

Planning
Phase of Trial: Phase III

Latest Information Update: 15 May 2018

At a glance

  • Drugs SD 101 Dynavax (Primary)
  • Indications B-cell lymphoma; Follicular lymphoma; Haematological malignancies; Head and neck cancer; Lymphoma; Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Dynavax Technologies
  • Most Recent Events

    • 15 May 2018 New trial record
    • 08 May 2018 According to a Dynavax Technologies media release, this trial is anticipated to begin in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top